Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ziekenhuis Oost-Limburg | OTHER |
Not provided
Not provided
Not provided
Not provided
Title Reaching out to the UNdiagnosed people infected with blood-borne viral infections (RUNtoBBV) Objectives 1. To study the efficacy of an outreach methodology to increase the uptake for screening, linkage to care and treatment in (active or former) people who use drugs (PWUD) Trial design Prospective multicenter interventional cohort design Number of subjects 336 inclusions (with prevalence of HCV Ab: 30%)
Selection criteria Inclusion criteria:
Main objectives:
Prevalence of blood-borne viral infections in Belgian (former or active) PWUD:
Analysis of linkage to care to hepatologist/ infectiologist (number of patients who adhered to their consultation/number of referred patients)
Secondary objectives:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| drug use | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| finger prick screening for BBV infections and questionnaires by outreaching methodology | Other | Screening by fingerprick for HCV Ab, HBsAg and HIV Ab and a questionnaire will be performed at sites outside of the regular treatment facilities. |
| Measure | Description | Time Frame |
|---|---|---|
| HCV Ab+ (Hepatitis C Virus antibody) | test using whole capillary blood (finger prick testing) | day 1 |
| HBsAg+ (Hepatitis B surface Antigen) | test using whole capillary blood (finger prick testing) | day 1 |
| HIV Ab+ (human immunodeficiency virus) antibody | test using whole capillary blood (finger prick testing) | day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| 4. Questionnaire to Identify risk factors associated with the aforementioned blood borne viral infections (hepatitis C, hepatitis B and HIV) | i. Combine results from positive finger prick test with questionnaire regarding sociodemographic factors, migration, risk factors for blood born viruses (sexual contacts, incarceration, drug use). The questionaire does not include a score on scale. | day 1 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Geert Robaeys, prof. dr. | Hasselt University | Principal Investigator |
| Rob Bielen, dr. | Hasselt University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Free Clinic Antwerpen | Antwerp | 2000 | Belgium | |||
| Free Clinic Antwerp |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34001145 | Derived | Busschots D, Kremer C, Bielen R, Koc OM, Heyens L, Dercon E, Verrando R, Windelinckx T, Maertens G, Bourgeois S, Hens N, Mathei C, Robaeys G. Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium. Harm Reduct J. 2021 May 17;18(1):54. doi: 10.1186/s12954-021-00502-7. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Analysis of uptake of anti(retro)viral treatment | percentage of HCV positive clients who started treatment in relation of total of HCV positive clients needing treatment | Day 1 |
| Analysis of treatment adherence | percentage of patients reaching end-of treatment response, who present at the consultation, in relation to total patients in treatment | up to one year |
| Analysis of treatment outcome | total number of cured or virally suppressed patients/total number of treated patients | month 18 |
| Antwerp |
| 2000 |
| Belgium |
| ZNA Antwerp | Antwerp | 2000 | Belgium |
| Ziekenhuis Oost-Limburg | Genk | 3600 | Belgium |
| CAD Limburg | Hasselt | 3500 | Belgium |
| Jessa Ziekenhuis | Hasselt | 3500 | Belgium |
| Ziekenhuis Maas en Kempen | Maaseik | Belgium |
| Mariaziekenhuis Noord-limburg | Overpelt | 3900 | Belgium |
| AZ Sint-Trudo | Sint-Truiden | 3800 | Belgium |
| AZ Vesalius | Tongeren | 3700 | Belgium |
| ID | Term |
|---|---|
| D006509 | Hepatitis B |
| D006526 | Hepatitis C |
| D000163 | Acquired Immunodeficiency Syndrome |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D018347 | Hepadnaviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D006525 | Hepatitis, Viral, Human |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D015658 | HIV Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
Not provided
Not provided